Skip to main content
SpringerLink
Log in

RBM38 in cancer: role and mechanism

  • Review
  • Published:
Cellular and Molecular Life Sciences Aims and scope Submit manuscript

Abstract

Cancer is the second leading cause of death globally. Abnormity in gene expression regulation characterizes the trajectory of tumor development and progression. RNA-binding proteins (RBPs) are widely dysregulated, and thus implicated, in numerous human cancers. RBPs mainly regulate gene expression post-transcriptionally, but emerging studies suggest that many RBPs can impact transcription by acting on chromatin as transcription factors (TFs) or cofactors. Here, we review the evidence that RBM38, an intensively studied RBP, frequently plays a tumor-suppressive role in multiple human cancer types. Genetic studies in mice deficient in RBM38 on different p53 status also establish RBM38 as a tumor suppressor (TS). By uncovering a spectrum of transcripts bound by RBM38, we discuss the diversity in its mechanisms of action in distinct biological contexts. Examination of the genomic features and expression pattern of RBM38 in human tissues reveals that it is generally lost but rarely mutated, in cancers. By assessing future trends in the study of RBM38 in cancer, we signify the possibility of targeting RBM38 and its related pathways as therapeutic strategies against cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(2018):394–424

    Article  PubMed  Google Scholar 

  2. Blackadar CB (2016) Historical review of the causes of cancer. World J Clin Oncol 7:54–86

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

    CAS  PubMed  Google Scholar 

  4. Pereira B, Billaud M, Almeida R (2017) RNA-binding proteins in cancer: old players and new actors. Trends Cancer 3:506–528

    Article  CAS  PubMed  Google Scholar 

  5. Hong S (2017) RNA binding protein as an emerging therapeutic target for cancer prevention and treatment. J Cancer Prev 22:203–210

    Article  PubMed  PubMed Central  Google Scholar 

  6. Aparicio LA, Abella V, Valladares M, Figueroa A (2013) Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition. Cell Mol Life Sci 70:4463–4477

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Glisovic T, Bachorik JL, Yong J, Dreyfuss G (2008) RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett 582:1977–1986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Xiao R, Chen JY, Liang Z, Luo D, Chen G, Lu ZJ, Chen Y, Zhou B, Li H, Du X, Yang Y, San M, Wei X, Liu W, Lecuyer E, Graveley BR, Yeo GW, Burge CB, Zhang MQ, Zhou Y, Fu XD (2019) Pervasive chromatin-RNA binding protein interactions enable RNA-based regulation of transcription. Cell 178:107–121

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bakacs A, Coppola L, Karni R (2011) Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 71:4464–4472

    Article  CAS  PubMed  Google Scholar 

  10. Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, Osawa T, Kanki Y, Minami T, Aburatani H, Ohmura M, Kubo A, Suematsu M, Takahashi K, Saya H, Nagano O (2012) Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 3:883

    Article  PubMed  CAS  Google Scholar 

  11. Wang X, Liu R, Zhu W, Chu H, Yu H, Wei P, Wu X, Zhu H, Gao H, Liang J, Li G, Yang W (2019) UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. Nature 571:127–131

    Article  CAS  PubMed  Google Scholar 

  12. Zhang J, Cho SJ, Shu L, Yan W, Guerrero T, Kent M, Skorupski K, Chen H, Chen X (2011) Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. Genes Dev 25:1528–1543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ding Z, Yang HW, Xia TS, Wang B, Ding Q (2015) Integrative genomic analyses of the RNA-binding protein, RNPC1, and its potential role in cancer prediction. Int J Mol Med 36:473–484

    Article  CAS  PubMed  Google Scholar 

  14. Shu L, Yan W, Chen X (2006) RNPC1, an RNA-binding protein and a target of the p53 family, is required for maintaining the stability of the basal and stress-induced p21 transcript. Genes Dev 20:2961–2972

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Zhang J, Jun Cho S, Chen X (2010) RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc Natl Acad Sci U S A 107:9614–9619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Jiang Y, Xu E, Zhang J, Chen M, Flores E, Chen X (2018) The Rbm38-p63 feedback loop is critical for tumor suppression and longevity. Oncogene 37:2863–2872

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Jiang Y, Zhang M, Qian Y, Xu E, Zhang J, Chen X (2014) Rbm24, an RNA-binding protein and a target of p53, regulates p21 expression via mRNA stability. J Biol Chem 289:3164–3175

    Article  CAS  PubMed  Google Scholar 

  18. Yang J, Hung LH, Licht T, Kostin S, Looso M, Khrameeva E, Bindereif A, Schneider A, Braun T (2014) RBM24 is a major regulator of muscle-specific alternative splicing. Dev Cell 31:87–99

    Article  CAS  PubMed  Google Scholar 

  19. Xu E, Zhang J, Zhang M, Jiang Y, Cho SJ, Chen X (2014) RNA-binding protein RBM24 regulates p63 expression via mRNA stability. Mol Cancer Res 12:359–369

    Article  PubMed  CAS  Google Scholar 

  20. Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, Chaffanet M, Birnbaum D, Bertucci F (2006) Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 12:4533–4544

    Article  CAS  PubMed  Google Scholar 

  21. Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, Eshhar Z, Orr-Urtreger A (2002) Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res 62:6803–6807

    CAS  PubMed  Google Scholar 

  22. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ (2000) Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 6:1833–1839

    CAS  PubMed  Google Scholar 

  23. Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M, Gray J, Waldman FM (1999) Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 25:82–90

    Article  CAS  PubMed  Google Scholar 

  24. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthai A, Cuesta MA (2009) Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 58:79–89

    Article  CAS  PubMed  Google Scholar 

  25. Hotte GJ, Linam-Lennon N, Reynolds JV, Maher SG (2012) Radiation sensitivity of esophageal adenocarcinoma: the contribution of the RNA-binding protein RNPC1 and p21-mediated cell cycle arrest to radioresistance. Radiat Res 177:272–279

    Article  CAS  PubMed  Google Scholar 

  26. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:1

    Article  CAS  Google Scholar 

  27. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(2020):7–30

    Article  PubMed  Google Scholar 

  28. Xue JQ, Xia TS, Liang XQ, Zhou W, Cheng L, Shi L, Wang Y, Ding Q (2014) RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer. BMC Cancer 14:322

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Zheng L, Zhang Z, Zhang S, Guo Q, Zhang F, Gao L, Ni H, Guo X, Xiang C, Xi T (2018) RNA binding protein RNPC1 inhibits breast cancer cell metastasis via activating STARD13-correlated ceRNA network. Mol Pharm 15:2123–2132

    Article  CAS  PubMed  Google Scholar 

  30. Shi L, Xia TS, Wei XL, Zhou W, Xue J, Cheng L, Lou P, Li C, Wang Y, Wei JF, Ding Q (2015) Estrogen receptor (ER) was regulated by RNPC1 stabilizing mRNA in ER positive breast cancer. Oncotarget 6:12264–12278

    Article  PubMed  PubMed Central  Google Scholar 

  31. Lou P, Li C, Shi L, Xia TS, Zhou W, Wu J, Zhou X, Li X, Wang Y, Wei JF, Ding Q (2017) RNPC1 enhances progesterone receptor functions by regulating its mRNA stability in breast cancer. Oncotarget 8:16387–16400

    Article  PubMed  Google Scholar 

  32. Dang CV (2012) MYC on the path to cancer. Cell 149:22–35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Li XX, Shi L, Zhou XJ, Wu J, Xia TS, Zhou WB, Sun X, Zhu L, Wei JF, Ding Q (2017) The role of c-Myc-RBM38 loop in the growth suppression in breast cancer. J Exp Clin Cancer Res 36:49

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Zhou XJ, Wu J, Shi L, Li XX, Zhu L, Sun X, Qian JY, Wang Y, Wei JF, Ding Q (2017) PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer. J Exp Clin Cancer Res 36:149

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Wu J, Zhou XJ, Sun X, Xia TS, Li XX, Shi L, Zhu L, Zhou WB, Wei JF, Ding Q (2017) RBM38 is involved in TGF-beta-induced epithelial-to-mesenchymal transition by stabilising zonula occludens-1 mRNA in breast cancer. Br J Cancer 117:675–684

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wang Y, Hou J, He D, Sun M, Zhang P, Yu Y, Chen Y (2016) The emerging function and mechanism of ceRNAs in cancer. Trends Genet 32:211–224

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Li X, Zheng L, Zhang F, Hu J, Chou J, Liu Y, Xing Y, Xi T (2016) STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer. Oncotarget 7:23197–23211

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ye J, Liang R, Bai T, Lin Y, Mai R, Wei M, Ye X, Li L, Wu F (2018) RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma. J Exp Clin Cancer Res 37:212

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Huang W, Wei XL, Ni W, Cao M, Meng L, Yang H (2017) The expression of RNA-binding protein RBM38 decreased in renal cell carcinoma and represses renal cancer cell proliferation, migration, and invasion. Tumour Biol 39:1010428317701635

    PubMed  Google Scholar 

  40. Wang P, Gu J, Li X, Wang Q, Ding Y (2017) RNA-binding protein RBM38 acts as a tumor suppressor in gastric cancer. Int J Clin Exp Pathol 10:11130–11136

    PubMed  PubMed Central  Google Scholar 

  41. Cheng G, Ji C, Yang N, Meng L, Ding Y, Wei J (2016) RNA-binding protein RBM38: Acting as a tumor suppressor in colorectal cancer. Int J Clin Exp Med 9:7115–7126

    CAS  Google Scholar 

  42. Yang L, Zhang Y, Ling C, Heng W (2018) RNPC1 inhibits non-small cell lung cancer progression via regulating miR-181a/CASC2 axis. Biotechnol Lett 40:543–550

    Article  CAS  PubMed  Google Scholar 

  43. Wampfler J, Federzoni EA, Torbett BE, Fey MF, Tschan MP (2016) The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation. Leuk Res 41:96–102

    Article  CAS  PubMed  Google Scholar 

  44. Xu E, Zhang J, Chen X (2013) MDM2 expression is repressed by the RNA-binding protein RNPC1 via mRNA stability. Oncogene 32:2169–2178

    Article  CAS  PubMed  Google Scholar 

  45. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17:211–215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Lin QY, Yin HL (2020) RBM38 induces SIRT1 expression during hypoxia in non-small cell lung cancer cells by suppressing MIR34A expression. Biotechnol Lett 42:35–44

    Article  CAS  PubMed  Google Scholar 

  47. Yan W, Zhang J, Zhang Y, Jung YS, Chen X (2012) p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability. Mol Cell Biol 32:2336–2348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Yin T, Cho SJ, Chen X (2013) RNPC1, an RNA-binding protein and a p53 target, regulates macrophage inhibitory cytokine-1 (MIC-1) expression through mRNA stability. J Biol Chem 288:23680–23686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Cho SJ, Jung YS, Zhang J, Chen X (2012) The RNA-binding protein RNPC1 stabilizes the mRNA encoding the RNA-binding protein HuR and cooperates with HuR to suppress cell proliferation. J Biol Chem 287:14535–14544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Cho SJ, Teng IF, Zhang M, Yin T, Jung YS, Zhang J, Chen X (2015) Hypoxia-inducible factor 1 alpha is regulated by RBM38, a RNA-binding protein and a p53 family target, via mRNA translation. Oncotarget 6:305–316

    Article  PubMed  Google Scholar 

  51. Zhang M, Xu E, Zhang J, Chen X (2015) PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38. Oncogene 34:5900–5911

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW (2006) p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9:45–56

    Article  CAS  PubMed  Google Scholar 

  53. Cho SJ, Zhang J, Chen X (2010) RNPC1 modulates the RNA-binding activity of, and cooperates with, HuR to regulate p21 mRNA stability. Nucleic Acids Res 38:2256–2267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Feldstein O, Ben-Hamo R, Bashari D, Efroni S, Ginsberg D (2012) RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation. Mol Cancer Res 10:1169–1177

    Article  CAS  PubMed  Google Scholar 

  55. Mazan-Mamczarz K, Galban S, Lopez de Silanes I, Martindale JL, Atasoy U, Keene JD, Gorospe M (2003) RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci U S A 100:8354–8359

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Leveille N, Elkon R, Davalos V, Manoharan V, Hollingworth D, Oude Vrielink J, le Sage C, Melo CA, Horlings HM, Wesseling J, Ule J, Esteller M, Ramos A, Agami R (2011) Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity. Nat Commun 2:513

    Article  PubMed  CAS  Google Scholar 

  57. Zhang Y, Feng X, Sun W, Zhang J, Chen X (2019) Serine 195 phosphorylation in the RNA-binding protein Rbm38 increases p63 expression by modulating Rbm38's interaction with the Ago2-miR203 complex. J Biol Chem 294:2449–2459

    Article  CAS  PubMed  Google Scholar 

  58. Zhang J, Xu E, Ren C, Yang HJ, Zhang Y, Sun W, Kong X, Zhang W, Chen M, Huang E, Chen X (2018) Genetic ablation of Rbm38 promotes lymphomagenesis in the context of mutant p53 by downregulating PTEN. Cancer Res 78:1511–1521

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Zhang M, Zhang J, Chen X, Cho SJ, Chen X (2013) Glycogen synthase kinase 3 promotes p53 mRNA translation via phosphorylation of RNPC1. Genes Dev 27:2246–2258

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Zhang J, Xu E, Ren C, Yan W, Zhang M, Chen M, Cardiff RD, Imai DM, Wisner E, Chen X (2014) Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors. Proc Natl Acad Sci USA 111:18637–18642

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Heinicke LA, Nabet B, Shen S, Jiang P, van Zalen S, Cieply B, Russell JE, Xing Y, Carstens RP (2013) The RNA binding protein RBM38 (RNPC1) regulates splicing during late erythroid differentiation. PLoS ONE 8:e78031

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Muller PA, Vousden KH (2014) Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25:304–317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER (2010) TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467:986–990

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445:661–665

    Article  CAS  PubMed  Google Scholar 

  65. Lucchesi CA, Zhang J, Ma B, Chen M, Chen X (2019) Disruption of the Rbm38-eIF4E complex with a synthetic peptide Pep8 increases p53 expression. Cancer Res 79:807–818

    Article  CAS  PubMed  Google Scholar 

  66. Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4:257–262

    Article  CAS  PubMed  Google Scholar 

  67. Zhang M, Zhang Y, Xu E, Mohibi S, de Anda DM, Jiang Y, Zhang J, Chen X (2018) Rbm24, a target of p53, is necessary for proper expression of p53 and heart development. Cell Death Differ 25:1118–1130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Hua WF, Zhong Q, Xia TL, Chen Q, Zhang MY, Zhou AJ, Tu ZW, Qu C, Li MZ, Xia YF, Wang HY, Xie D, Claret FX, Song EW, Zeng MS (2016) RBM24 suppresses cancer progression by upregulating miR-25 to target MALAT1 in nasopharyngeal carcinoma. Cell Death Dis 7:e2352

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Zhang D, Hu Q, Ji Y, Chao HP, Liu Y, Tracz A, Kirk J, Buonamici S, Zhu P, Wang J, Liu S, Tang DG (2020) Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nat Commun 11(1):2089

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Lu X, Nannenga B, Donehower LA (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19:1162–1174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This project was supported by Grants from the National Natural Science Foundation of China 81972418 (to D. Z.) and 31871481 (to Z. D.), the Wuhan Frontier Science and Technology Program 2019020701011490 (to D. Z.) and the Fundamental Research Funds for the Central Universities 531119200130 (to D. Z.) and 2662017PY109 (to Z. D).

Author information

Author notes

  1. Cheng Zou and Ying Wan contributed equally to this work.

Authors and Affiliations

  1. College of Biology, Hunan University, Changsha, 410082, China

    Cheng Zou, Lingjing He, Jin Hai Zheng, Yang Mei, Junfeng Shi & Dingxiao Zhang

  2. College of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China

    Ying Wan, Min Zhang & Zhiqiang Dong

Authors
  1. Cheng Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lingjing He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jin Hai Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yang Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Junfeng Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Min Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhiqiang Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dingxiao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhiqiang Dong or Dingxiao Zhang.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zou, C., Wan, Y., He, L. et al. RBM38 in cancer: role and mechanism. Cell. Mol. Life Sci. 78, 117–128 (2021). https://doi.org/10.1007/s00018-020-03593-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00018-020-03593-w

Keywords

Search

Navigation